KeYe Life has been running for 6 full years, aiming to develope innovative drugs from the very beginning stage. Innovation to improve the quality of life has been the mission of KeYe Life all the time. Although encountering a difficult time during 2025, KeYe Life team still made many remarkable achievements during the past year.

1.  In February and June of 2025, KeYe Life received“ Study may proceed”notice issued from FDA and CDE, approving the Phase I clinical trials of KY2 liquid capsules for the treatment of late stage solid tumors. KY2 is the second product independently developed in KeYe Life.

2. Successful registration of 3 Category 1 medical devices in June, 2025, certified for ISO13485, a quality system for medical devices.

3.  In July 2025, KeYe Life successfully registered for its pathogenic microorganism laboratory on national, provincial, and municipal platforms, allowing to detect pathogen microorganism in pharmaceutical samples.

4.  In March 2025,  KeYe Life successfully developed multiple hybridoma cell lines that secrete specific antibodies recognizing RNA helicases, enabling the development and manufacturing of companion diagnostic reagents.

5. A helicase activity assay platform has been established, covering 35 members of the RNA helicase family. The RNA helicase family includes about 70 members and is involved in various processes of RNA metabolism. Currently, there are no publicly available service that provide enzymatic activity analysis for most members of this family. In this context, KeYe Life has independently cloned and purified over 50% of the RNA helicase family proteins for future drug activity assays of RNA helicase inhibitors.      

6.  In August 2025, the first-in-class drug product KY1 achieved a partial response (PR) in early clinical trials. KY1 showed a significant partial response in the treatment of a patient with intrahepatic cholangiocarcinoma.

7.  KeYe Life's innovative targeting technology has gained widespread recognition: it won the second prize in the Biomedicine field at the finals of the 17th Shenzhen Innovation and Entrepreneurship Competition in September 2025, received the Excellence Award at the 14th China Innovation and Entrepreneurship Competition in November 2025 with a comprehensive judges' score of 89.79, and won the Excellence Award at the 11th 'Jingniu Hui' Zhuhai Innovation and Entrepreneurship Competition.

8.  In 2025, a total of 12 invention patents were applied, and 7 new patents were granted.

Looking ahead, the KeYe Life will continue to uphold the spirit of innovation, as well as a down-to-earth, rigorous, and efficient professional attitude, to achieve new milestones in drug research and development.